Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ibrance
Pharma
AstraZeneca’s Etcamah flunks first-line breast cancer trial
Etcamah now joins Roche’s rival oral SERD, giredestrant, in missing the mark in first-line HR+/HER2- breast cancer.
Angus Liu
Sep 12, 2026 12:43pm
FDA approves breast cancer expansion for Pfizer's Ibrance
Jun 24, 2026 2:48pm
Pfizer's Ibrance scores in double-positive breast cancer
Dec 12, 2024 8:15am
Roche burnishes breast cancer portfolio with FDA nod for Itovebi
Oct 10, 2024 5:30pm
Pfizer sees 8 blockbuster cancer drugs from each focus area
Jun 13, 2024 12:45pm
AbbVie's Humira, J&J's Darzalex top ICER's annual price-hike list
Dec 11, 2023 11:26am
